AlphAIAlphAI — Financial news for AI agents
tradingview.com$AMGN

Leerink Partners maintains Amgen at Market Perform, raises price target to $464 from $395

Leerink Partners kept Amgen's rating at Market Perform but increased its price target to $464 from $395, a 17.5% rise. This aligns with Amgen's recent close of $460.28. Recent analyst targets for Amgen range from $435 to $530.

Original reporting
tradingview.com
Published Nov 5, 2026, 9:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Leerink Partners maintains Amgen at Market Perform, raises price target to $464 from $395 — source image
Source · tradingview.com
Decision brief

The 30-second read

$AMGNBullishMed
01

Why it matters

The price target increase reflects confidence in Amgen's pipeline and earnings outlook.

02

Market read

Analyst target raise may prompt short-term buying interest in AMGN.

03

What to watch

Potential pipeline setbacks or regulatory risks not addressed in the note.

Relevance 6/10Novelty 6/10Timing: today

Background

Amgen is a large-cap biotech company; analyst upgrades can move its stock.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Leerink Partners raised Amgen's price target to $464 from $395, indicating a bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Analyst upgrade and higher price target typically lead to buying interest.

Market effects

Sector

Biotech sector may see modest uplift from analyst optimism on Amgen.

Regional

US biotech investors could adjust exposure.

Global

Limited to Amgen and peers.

Counterpoint

What could challenge this read

Target raise may be premature if upcoming trial data disappoints.

Key entities

  • company
    Amgen

    Biopharmaceutical company receiving the rating upgrade.

  • analyst_firm
    Leerink Partners

    Equity research firm that raised the price target.

Read at source← All news

Related articles

$AMGNMed

Freedom Broker downgrades Amgen stock rating on valuation despite raising price target

Freedom Broker downgraded Amgen (AMGN) to Hold from Buy, raising its price target to $470. The move follows strong quarterly results, with revenue and EPS beating expectations. Amgen raised its full-year guidance, and shares are up 44% year-to-date. Analysts cite strong performance but note the stock is near fair value. Other analysts, including UBS and RBC, raised their price targets.

investing.com
$AMGNLow

FDA Approval for AMJEVITA issued to AMGEN INC

The FDA approved a label update for Amgen's AMJEVITA (adalimumab-atto) on 11/05/2026, according to the company. The approval covers the 20 mg/0.4 mL and 40 mg/0.8 mL injectable products, but no new indication was disclosed. This is a routine regulatory update for an already approved product.

quantisnow.com
$AMGNMed

Amgen’s Repatha reduces heart attack risk in real-world study

Amgen's Repatha (evolocumab) reduced heart attack risk by 20% compared to ezetimibe in a real-world study of 544,103 adults with atherosclerotic cardiovascular disease, according to the company. The four-year study tracked patients from 2017 to 2024, with Repatha showing a lower cumulative incidence of heart attacks (5.88% vs. 7.76%). Amgen's chief medical officer highlighted the study's relevance for treatment decisions.

clinicaltrialsarena.com